drugset
drugset / Trial / NCT04516382

Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers

NCT04516382 ↗

Phase 1 Completed 12 enrolled Protagonist Therapeutics, Inc.
Non-randomizedCrossoverOpen-labelOther

Summary

To estimate the bioavailability of PTG-300 following subcutaneous and intramuscular administration in healthy volunteers.

Timeline

Start
2020-09-14
Primary completion
2021-01-12
Completion
2021-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Rusfertide Peptide 1.5 mg Intravenous
Subject Rusfertide Peptide 40 mg Intravenous

Indications

No indication recorded.